Application 211583
- Type
- ANDA
- Sponsor
- TEVA PHARMS USA INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | 2.5MG/1000MG | No | No |
| 002 | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | 5MG/500MG | No | No |
| 003 | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | 5MG/1000MG | No | No |
| 004 | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | 10MG/500MG | No | No |
| 005 | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN;METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | 10MG/1000MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211583-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 2.5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | ||
| A211583-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | ||
| A211583-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | ||
| A211583-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | ||
| A211583-005 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211583-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2.5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | d4dbc9d85df4… | ||
| 2026-11-14 07:37:17 | 2026-10 | A211583-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | d4dbc9d85df4… | ||
| 2026-11-14 07:37:17 | 2026-10 | A211583-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | d4dbc9d85df4… | ||
| 2026-11-14 07:37:17 | 2026-10 | A211583-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | d4dbc9d85df4… | ||
| 2026-11-14 07:37:17 | 2026-10 | A211583-005 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | 2026-04-06 | d4dbc9d85df4… | ||
| 2026-10-15 13:18:30 | 2026-09 | A211583-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2.5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211583-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211583-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211583-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211583-005 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A211583-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2.5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211583-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211583-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211583-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211583-005 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A211583-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2.5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211583-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211583-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211583-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211583-005 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2.5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-005 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A211583-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211583-002 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211583-003 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211583-004 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211583-005 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A211583-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211583-002 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211583-003 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211583-004 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211583-005 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A211583-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211583-002 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211583-003 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211583-004 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211583-005 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-002 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-003 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-004 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211583-005 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 72027 | ORIG | 2022-09-07 |